Alembic Pharmaceuticals Sustainability Profile
Alembic Pharmaceuticals Limited, commonly referred to as Alembic, is a prominent player in the global pharmaceutical industry, headquartered in Vadodara, India. Established in 1907, the company has a rich history marked by significant milestones, including its expansion into regulated markets and the development of a robust portfolio of generic and branded formulations. Alembic operates primarily in the areas of pharmaceuticals, biotechnology, and active pharmaceutical ingredients (APIs), focusing on therapeutic segments such as cardiovascular, anti-infective, and central nervous system disorders. The company is renowned for its commitment to quality and innovation, which is reflected in its extensive range of products that meet stringent international standards. With a strong market position, Alembic Pharmaceuticals has achieved notable success, including multiple approvals from regulatory authorities worldwide. Its dedication to research and development, coupled with a strategic approach to global expansion, solidifies its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Alembic Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alembic Pharmaceuticals's score of 58 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alembic Pharmaceuticals's reported carbon emissions
In 2025, Alembic Pharmaceuticals, headquartered in India, reported significant carbon emissions, with Scope 1 emissions totalling approximately 80,278,030 kg CO2e and Scope 2 emissions at about 77,965,980 kg CO2e. The company has set ambitious climate commitments, aiming for a 63% reduction in absolute greenhouse gas emissions across all scopes by 2034, using 2022 as the base year. Furthermore, Alembic has committed to achieving net-zero emissions by 2050, with a long-term target of reducing emissions by 90% from the same base year. In 2024, the company reported Scope 1 emissions of about 86,096,000 kg CO2e, Scope 2 emissions of approximately 67,544,000 kg CO2e, and Scope 3 emissions reaching around 756,174,000 kg CO2e. This indicates a comprehensive approach to emissions management, covering all three scopes, which is essential for a holistic climate strategy. Alembic Pharmaceuticals' reduction targets are aligned with the Science Based Targets initiative (SBTi), ensuring that their goals are consistent with the global effort to limit temperature rise to 1.5°C. The company is actively working towards these targets, demonstrating a commitment to sustainability and environmental responsibility within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is Alembic Pharmaceuticals's Industry?
How Carbon Intensive is Alembic Pharmaceuticals's Location?
Alembic Pharmaceuticals's Scope 3 Categories Breakdown
Alembic Pharmaceuticals's Scope 3 emissions, which increased by 17% last year and increased by approximately 17% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 70% of Scope 3 emissions.
Top Scope 3 Categories
Alembic Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alembic Pharmaceuticals has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
GlaxoSmithKline Pharmaceuticals Limited
Frequently Asked Questions
Common questions about Alembic Pharmaceuticals's sustainability data and climate commitments